Immune cell combo shows promise in tough head and neck cancers
NCT ID NCT04290546
First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 2 times
Summary
This early-phase trial tested a new approach for people with advanced head and neck cancer that has come back or spread. It combined specially trained natural killer (NK) immune cells with drugs that help the immune system attack cancer. The study enrolled 11 participants to check safety and see if tumors shrink.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADENOID CYSTIC CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can Pre-Surgery immunotherapy prime the immune system to fight head and neck cancer?
- Can a new drug boost the power of chemoradiation against head and neck cancer?
- Can a new drug combo shrink Hard-to-Treat salivary gland tumors?
- Can immunotherapy boost surgery outcomes in recurrent head and neck cancer?
- Can a targeted drug shrink rare salivary gland tumors?
- Can a Three-Pronged attack shrink Hard-to-Treat head and neck cancers?